31 maj: Europa/luk: Tro på irsk "ja" banket ned af USA-tal
01 jun: Selskabernes forventninger - fredag den 1 juni
01-06-2012 00:14:00

UK Regulator Draft Guidance Recommends Bayer's Xarelto For Blood Clots

Relateret indhold
Relateret debat
16 maj - 
We can deliver Financial service/instruments(BG/SBLC/MT..
16 maj - 
FDA NEWS RELEASE For Immediate Release: Dec. 4, 2013 Me..
19 apr - 
Sikke dog noget tømmermændssnak GW. Fordi du ikke kom m..

FRANKFURT -(Dow Jones)- The U.K. drug regulator has recommended the use of Xarelto, a drug produced by a unit of Bayer AG (BAYN.XE), to treat blood clots, according to draft final guidance published Friday.

The guidance is likely to result in a recommendation from the National Institute for Health and Clinical Excellence, known as NICE, meaning the U.K. public health-care system will offer the drug and pay for it. The draft guidance is now with consultees, who have the opportunity to appeal against it.

"Bayer Healthcare welcomes this draft final appraisal determination recommendation from NICE because it simplifies the treatment of venous blood clot treatment for physicians and their patients," Bayer spokeswoman Astrid Kranz said.

Earlier, NICE had asked Bayer to provide more information on the drug. The move follows a May 22 approval for Xarelto for stroke prevention and systemic embolism in people with atrial fibrillation.

If the final approval is given, Xarelto, also known as Rivaroxaban, may then be offered as an alternative to injectable anticoagulants such as low-molecular-weight heparin or fondaparinux sodium, overlapped with a vitamin-K antagonist, such as warfarin.

It is estimated that there will be over 46,000 cases of acute deep vein thrombosis, or DVT, in England and Wales during 2012, rising to nearly 50,000 by 2016 due in large part to the aging population, NICE said.

"Xarelto is the first only novel oral anticoagulant offering a unique single drug solution for the treatment of DVT in adults," Kranz said.

On May 24, Bayer confirmed it expects peak sales of Xarelto of above EUR2 billion annually. The drug, which is being co-developed by Bayer and U.S. drug maker Johnson & Johnson (JNJ), is a rival of Boehringer Ingelheim GmbH's Pradaxa.

-By Monica Houston-Waesch, Dow Jones Newswires; +49 69 29 725 504; nikki.houston@dowjones.com

(END) Dow Jones Newswires

May 31, 2012 18:14 ET (22:14 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/tendens: Udsigt til let vigende aktier efter fald i USA

24-05-2016 08:13:54
Pilen ser ud til at ville pege en smule ned for det danske aktiemarked tirsdag morgen, hvor en lille håndfuld mindre selskaber er klar med regnskaber for første..

Arkil-konsortium taber kontrakt hos Banedanmark

23-05-2016 15:29:01
Banedanmark har mandag ophævet kontrakten med konsortiet Strukton Rail om sporombygningsarbejde på Østfyn efter problemerne med togdriften i Kristi himmelfarts-..

Genmab får kræfthåb godkendt i Europa - NY

23-05-2016 13:15:30
Biotekselskabet Genmab kan nu også begynde at sælge kræftmidlet Darzalex på det europæiske marked, da EU-Kommissionen har givet midlet markedsføringstilladelse...

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab får kræfthåb godkendt i Europa - NY
2
Bavarian opnår positive resultater med vaccine mod RS-virus -NY
3
Vestas-dir: Innovation eller vi dør
4
Arkil-aktien røg af sporet
5
Mandagens aktier: Genmab sprintede fra C20-feltet

Relaterede aktiekurser

Johnson & Johnson 112,16 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. maj 2016 11:56:46
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160517.1 - EUROWEB6 - 2016-05-24 11:56:46 - 2016-05-24 11:56:46 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x